Section Arrow
Quote
NKTR.NASDAQ
- Nektar Therapeutics
Quotes are at least 15-min delayed:2026/04/21 23:24 EDT
Regular Hours
Last
 98.16
-2.19 (-2.18%)
Day High 
106.42 
Prev. Close
100.35 
1-M High
109 
Volume 
1.60M 
Bid
98.25
Ask
98.7
Day Low
96.23 
Open
103 
1-M Low
64.1 
Market Cap 
2.88B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 82.08 
20-SMA 77.22 
50-SMA 72.03 
52-W High 109 
52-W Low 7.99 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-9.73/-13.15
Enterprise Value
2.94B
Balance Sheet
Book Value Per Share
3.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
55.23M
Operating Revenue Per Share
3.08
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.